Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation.

[1][2][3] It reached phase III clinical trials for this indication before being discontinued.

[4][5]

This drug article relating to the gastrointestinal system is a stub.

You can help Wikipedia by expanding it.